Sign in Subscribe
COVID-19

Synthetic Host Defense Peptide Shows Promise in Treating SARS-CoV-2 and Influenza A Virus

Strategic Insights

— 1 min read

Researchers at the Schulich School of Medicine and Dentistry have made significant discoveries regarding the potential use of a synthetic host defense peptide, D-3006, in treating SARS-CoV-2 and other respiratory viral infections. According to a study published in Antimicrobial Agents and Chemotherapy, D-3006 demonstrated broad-spectrum antiviral activity, effectively inhibiting SARS-CoV-2 replication in vitro and also showing promise against influenza A virus.

Key Takeaways:

  • D-3006, a synthetic host defense peptide, showed potential in inhibiting SARS-CoV-2 replication in vitro, with a safe concentration of 430 μg/mL.
  • The peptide demonstrated synergistic anti-SARS-CoV-2 activity when combined with the viral polymerase inhibitor remdesivir.
  • D-3006 also exhibited antiviral activity against influenza A virus (H1N1) in vitro, suggesting broad-spectrum antiviral potential.
  • The mechanism of action of D-3006 involves non-specific binding to the viral membrane, causing virus aggregation and interfering with virus attachment and entry.
  • The researchers suggest that D-3006 could be developed as a candidate for the treatment of SARS-CoV-2 and other respiratory viral infections.
  • The study was funded by the New Zealand Ministry of Business, Innovation and Employment (MBIE) and Quidel.
  • The research team included Miguel E. Quinones-Mateu, Rhodri Harfoot, Blair Lawley, Joanna Kuang, and other notable researchers.

Statistics:

  • The concentration of D-3006 required to inhibit SARS-CoV-2 replication in vitro was 430 μg/mL (EC50 value).
  • The peptide showed synergistic anti-SARS-CoV-2 activity when combined with remdesivir, with a 5.37 μg/mL EC50 value.
  • D-3006 demonstrated antiviral activity against influenza A virus (H1N1) in vitro, with a 1.57-5.37 μg/mL EC50 value.
  • The number of SARS-CoV-2 variants tested was 4 (ancestral, Mu, Delta, and Omicron BA.1).
  • The number of beta-coronavirus spike pseudotyped lentiviruses tested was not explicitly stated.

Sources:

  • (Antimicrobial Agents and Chemotherapy, 2025)
  • (Amer Soc Microbiology, 1752 N St NW, Washington, DC 20036-2904, USA)
  • (American Society for Microbiology - www.asm.org; Antimicrobial Agents and Chemotherapy - aac.asm.org)
  • (NewsRx, 2025, Reports from Schulich School of Medicine and Dentistry Highlight Recent Findings in Influenza A Virus (Synthetic Host Defense Peptide Inhibits Sars-cov-2 Replication in Vitro). Medical Letter on the CDC & FDA. July 20, 2025; p 162.)

Read more